Brain Cancer Therapeutic Pipeline Review H1 2015 Market Research Report at

Share Article adds “Brain Cancer - Pipeline Review, H1 2015” to its store. The report provides an overview of the Brain Cancer’s therapeutic pipeline.

Brain Cancer Therapeutic Pipeline Review H1 2015

Brain Cancer Therapeutic Pipeline Review H1 2015

The report "Brain Cancer – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Brain Cancer. Brain cancer is a tumour or cancerous development in the brain. A main brain tumor starts in the brain. A metastatic brain tumor starts anywhere else in the body and moves to the brain. Almost all tumors that begin in the brain do not spread to other parts of the body. Brain cancer can have a wide range of symptoms including seizures, sleepiness, confusion, nausea and vomiting, behavioral changes and muscle jerking. Brain tumours in children are different from those in adults and are often treated in a different way. Treatment for brain cancer should be individualized for each patient. In most cases of brain cancer surgery, radiation and chemotherapy are the main types of treatment. Complete Report is Available @ .

It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects. Companies discussed in this Brain Cancer Pipeline Review H1 2015 report include AbbVie Inc., AngioChem Inc., Arrien Pharmaceuticals, LLC, BBB Therapeutics B.V., biOasis Technologies Inc., Bionomics Limited, Bristol-Myers Squibb Company, Cavion LLC, Critical Outcome Technologies Inc., CureFAKtor Pharmaceuticals, LLC, Diffusion Pharmaceuticals LLC, e-Therapeutics plc, Eisai Co., Ltd., Exelixis, Inc., GlaxoSmithKline plc, Hutchison MediPharma Limited, Merrimack Pharmaceuticals, Inc., Nanobiotix, Nektar Therapeutics, Nerviano Medical Sciences S.r.l., Neuralstem, Inc., Novartis AG, Oncology Research International Limited, Pfizer Inc., Philogen S.p.A., Phosplatin Therapeutics, Prana Biotechnology Limited, Puma Biotechnology, Inc., RadioRx, Inc., Sagetis Biotech, S.L., Sanofi, Spectrum Pharmaceuticals, Inc., Stemline Therapeutics, Inc., Takeda Pharmaceutical Company Limited, ThromboGenics NV, Tocagen Inc., Zymeworks Inc.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Order a Purchase copy of this report @ . (This is a premium report priced at US$2000 for a single user License.)

Drug Profiles discuss in this report include 2B3-101, ANG-1005, ANG-4043, ARN-7016, BNC-105, BT-2111, cabazitaxel, cabozantinib s-malate, CFAKC-4, COTI-2, dabrafenib mesylate, dacomitinib, dexanabinol, erismodegib, etirinotecan pegol, HMPL-813, ipilimumab, irinotecan sucrosofate liposomal, lapatinib ditosylate, ubidecarenone, TB-403, TBX-02 etc.

Table of Contents

List of Tables

Number of Products under Development for Brain Cancer, H1 2015 14
Number of Products under Development for Brain Cancer – Comparative Analysis, H1 2015 15
Number of Products under Development by Companies, H1 2015 17
Number of Products under Development by Companies, H1 2015 (Contd..1) 18
Number of Products under Development by Companies, H1 2015 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H1 2015 20
Comparative Analysis by Late Stage Development, H1 2015 21
Comparative Analysis by Clinical Stage Development, H1 2015 22
Comparative Analysis by Early Stage Development, H1 2015 23
Products under Development by Companies, H1 2015 24
Products under Development by Companies, H1 2015 (Contd..1) 25
Products under Development by Companies, H1 2015 (Contd..2) 26
Products under Development by Companies, H1 2015 (Contd..3) 27
Products under Investigation by Universities/Institutes, H1 2015 28
Brain Cancer – Pipeline by AbbVie Inc., H1 2015 29
Brain Cancer – Pipeline by AngioChem Inc., H1 2015 30
Brain Cancer – Pipeline by Arrien Pharmaceuticals, LLC, H1 2015 31
Brain Cancer – Pipeline by BBB Therapeutics B.V., H1 2015 32
Brain Cancer – Pipeline by biOasis Technologies Inc., H1 2015 33
Brain Cancer – Pipeline by Bionomics Limited, H1 2015 34
Brain Cancer – Pipeline by Bristol-Myers Squibb Company, H1 2015 35
Brain Cancer – Pipeline by Cavion LLC, H1 2015 36
Brain Cancer – Pipeline by Critical Outcome Technologies Inc., H1 2015 37
Brain Cancer – Pipeline by CureFAKtor Pharmaceuticals, LLC, H1 2015 38
Brain Cancer – Pipeline by Diffusion Pharmaceuticals LLC, H1 2015 39
Brain Cancer – Pipeline by e-Therapeutics plc, H1 2015 40
Brain Cancer – Pipeline by Eisai Co., Ltd., H1 2015 41
Brain Cancer – Pipeline by Exelixis, Inc., H1 2015 42
Brain Cancer – Pipeline by GlaxoSmithKline plc, H1 2015 43
Brain Cancer – Pipeline by Hutchison MediPharma Limited, H1 2015 44
Brain Cancer – Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 45
Brain Cancer – Pipeline by Nanobiotix, H1 2015 46
Brain Cancer – Pipeline by Nektar Therapeutics, H1 2015 47
Brain Cancer – Pipeline by Nerviano Medical Sciences S.r.l., H1 2015 48
Brain Cancer – Pipeline by Neuralstem, Inc., H1 2015 49

Explore more reports on Pharmaceuticals industry at .

About Us: is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
Follow >
Market Reports China
Like >
Follow us on
Visit website